PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients with Kras Wild-Type Tumours in the United Kingdom
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1171
https://www.valueinhealthjournal.com/article/S1098-3015(11)02733-1/fulltext
Title :
PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients with Kras Wild-Type Tumours in the United Kingdom
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02733-1&doi=10.1016/j.jval.2011.08.1171
First page :
A446
Section Title :
Cancer
Open access? :
No
Section Order :
1128